AstraZeneca has extended its multiyear collaboration with Immunai to incorporate its AI-powered immune cell atlas in the design of clinical trials for cancer immunotherapies. The partnership, which began with research into inflammatory bowel disease, aims to improve patient selection by analyzing immune system profiles. Immunai will receive $18 million for the first phase of the project, with AstraZeneca retaining the option to expand the collaboration's scope.
Immunai previously contributed its multi-omics technology to the development of AstraZeneca’s bispecific antibody volrustomig, currently in phase 3 trials for lung, cervical, and head and neck cancers. Immunai’s AI platform, including its Immunodynamics Engine (IDE), has been instrumental in mapping immune cell interactions and advancing drug development. The partnership builds on Immunai’s broader work in immuno-oncology, auto-immune, cardiovascular, and neurological diseases.
This extended collaboration will focus on enhancing clinical decision-making, dose selection, and biomarker identification, aiming to make drug development more efficient. Immunai CEO Noam Solomon emphasized the potential to expedite the complex, costly process of bringing new therapies to market, leveraging the IDE platform to improve outcomes for cancer patients through more targeted treatments.
Click here to read the original news story.